We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
- Authors
Kijima, Toshiki; Fujii, Yasuhisa; Yokoyama, Minato; Ishioka, Junichiro; Matsuoka, Yoh; Numao, Noboru; Saito, Kazutaka; Koga, Fumitaka; Masuda, Hitoshi; Kawakami, Satoru; Kihara, Kazunori
- Abstract
What's known on the subject? and What does the study add? The additional use of anti-androgen (deferred combined androgen blockade [CAB] therapy) for patients with castration-resistant prostate cancer (CRPC) initially treated with androgen deprivation monotherapy (ADMT) can provide a clinical response, although the reported response rates vary widely. Our previous study, which reported a response rate of 66% to deferred CAB therapy, suggested that deferred CAB responders would also respond better to subsequent therapies than non-responders because the difference in cancer-specific survival between the deferred CAB responders and the non-responders was much larger than the progression-free survival rates for the responders. The present study showed that PSA response to deferred CAB therapy predicts clinical outcomes after subsequent oestrogen and docetaxel therapy. We propose that PSA response to deferred CAB be used for planning individualized treatment that includes secondary hormonal therapy and chemotherapy.
- Publication
BJU international, 2012, Vol 110, Issue 8, p1149
- ISSN
1464-410X
- Publication type
Journal Article
- DOI
10.1111/j.1464-410X.2012.10959.x